GLP-1 Titration Schedule: Doses, Timing, Missed Injections, and Plateaus

Semaglutide (marketed as Wegovy for chronic weight management and Ozempic for type 2 diabetes) and tirzepatide (marketed as Zepbound for weight management and Mounjaro for type 2 diabetes) are both injectable GLP-1 receptor agonists; tirzepatide additionally activates the GIP receptor. Patients do not begin treatment at the maintenance dose. Instead, both medications follow a fixed, FDA-labeled dose escalation over several months, which serves as an active clinical management strategy rather than merely a procedural requirement.

The direct answer: Wegovy's approved titration moves through five doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) at four-week intervals, reaching the 2.4 mg maintenance dose at week 17 at the earliest. Zepbound's approved titration moves through six doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) at four-week intervals, with 5 mg, 10 mg, and 15 mg all recognized as acceptable maintenance doses. Both schedules exist to reduce the nausea and vomiting that cause early discontinuation, not to slow weight loss, and both are the same schedules used in the trials that established each drug's efficacy. Missed-dose handling, plateau management, and whether to stay on a lower dose all depend on individualized response and are not fully specified by the label.

The underlying question for most patients is not "how fast can I reach the top dose," but "what is the slowest, most sustainable path to a dose I can actually tolerate and stay on." Trial data consistently show that stopping the drug, not staying at a lower dose, is what drives weight regain.

Why the ramp exists

GLP-1 receptor agonists slow gastric emptying and reduce appetite through hypothalamic and vagal signaling. That same gastric-slowing effect is the mechanism behind the nausea, bloating, and constipation that are the most common reasons patients stop treatment early. Titrating slowly gives the gut time to adapt.

The FDA-approved schedules for both drugs were the schedules used in their pivotal trials (the STEP program for semaglutide and the SURMOUNT program for tirzepatide), not separately chosen conservative estimates. Skipping steps, shortening the four-week intervals, or jumping doses is off-label and is associated with a higher rate of gastrointestinal side effects severe enough to cause discontinuation before a therapeutic dose is reached. If a step causes side effects that are hard to tolerate, extending that step for an additional four weeks before advancing is consistent with labeling for both drugs, and is a common and reasonable clinical adjustment.

Semaglutide titration (Wegovy and Ozempic)

This reflects current FDA-approved labeling for Wegovy and Ozempic as of this writing; dosing information changes periodically, and the current label should always be checked directly at the FDA's Drugs@FDA database before making a dosing decision.

Ozempic's approved ceiling for glycemic control is 2.0 mg. The 2.4 mg dose is approved only under the Wegovy label for chronic weight management, not for diabetes treatment, even though it is the same molecule.

Trial evidence (the STEP program) established that semaglutide 2.4 mg produces substantially greater mean weight loss than placebo over roughly 68 weeks, and a head-to-head trial in the same program reported greater weight loss with semaglutide 2.4 mg than with liraglutide 3.0 mg over a similar period. Exact percentage figures are widely reported in secondary sources but should be verified against the original NEJM and JAMA publications before being used in patient-facing or clinical materials, since this draft does not carry a confirmed direct link to the specific trial reports.

Tirzepatide titration (Zepbound and Mounjaro)

Zepbound's label designates 5 mg, 10 mg, and 15 mg as maintenance doses; 2.5 mg, 7.5 mg, and 12.5 mg are titration steps only. A patient who tolerates 10 mg well and is losing weight has no label requirement to advance further.

The SURMOUNT program (SURMOUNT-1 through SURMOUNT-4) established tirzepatide's efficacy and, in SURMOUNT-2, its use in adults with type 2 diabetes at the same titration steps used for weight management. As with the STEP program, specific percentage or A1c figures reported in secondary summaries should be checked against the original publications before being treated as exact.

There is no published head-to-head randomized trial directly comparing semaglutide and tirzepatide titration outcomes. Any claim that one drug's ramp produces faster or greater weight loss than the other's at matched titration weeks is an inference from separate trials with different populations and should be presented as such, not as a direct comparison.

Missed-dose rules

FDA labeling for both Wegovy and Zepbound uses a five-day window for missed doses:

• Within 5 days of the missed dose: inject as soon as possible, then resume the normal weekly schedule on the original day the following week. Do not take two doses close together.
• 6 or more days after the missed dose: skip the missed dose entirely and wait for the next scheduled day. Do not "catch up."

Repeated missed doses over multiple weeks are not fully addressed by either label. Beyond roughly four weeks without an injection, many prescribers restart at a lower dose step to reduce the risk of nausea and vomiting on restart, on the reasoning that gastrointestinal tolerance built up during titration fades over time. This is clinical judgment, not a label rule, and the correct restart point should be decided with the prescribing clinician rather than by the patient alone.

Pens stored outside the labeled refrigerator range for longer than the manufacturer's specified limit should be discarded rather than used, since heat-exposed medication may lose potency unpredictably without an obvious change in appearance.

What a weight-loss plateau does and doesn't mean

A reasonable clinical definition of a plateau is less than roughly 1% body weight change over 12 consecutive weeks at a stable, unchanged dose. Fewer than 12 weeks of stable weight is too early to call a plateau, since normal week-to-week fluctuation and slowing of the rate of loss (a near-universal pattern as total weight lost increases and resting energy expenditure falls) can look similar to a true plateau in the short term.

Long-term follow-up data from the STEP and SURMOUNT programs show that weight loss can continue well beyond the point where the rate of loss slows, and that patients who stop the medication (even after a long period of successful treatment) tend to regain a substantial portion of lost weight within about a year, while those who continue treatment tend to maintain or continue to lose. This is the strongest evidence that discontinuation, not the plateau itself, is usually what reverses progress. Exact percentages from these trials should be confirmed against the original publications before being quoted precisely.

GLP-1 titration monitoring and escalation framework

The titration framework presented here is designed to guide clinical conversations and assessments at each dose transition, not to replace individualized decision-making. It clarifies the distinction between FDA-specified dosing protocols and the clinical judgment required to manage each patient's response.

Checkpoint 1: Before each dose increase (every 4 weeks)

• Label guidance: do not advance if the current step has not been tolerated; extending a step by four weeks is within labeling for both drugs.
• Ask: any vomiting more than twice a week, any inability to keep fluids down, any signs of dehydration, any severe or worsening abdominal pain radiating to the back.
• Site judgment: adherence review (injection technique, storage, missed doses) before assuming a poor response is drug-related.
• Stop/hold condition: hold the dose (do not advance) if vomiting has occurred more than twice in the prior week, or if there is any suspicion of pancreatitis (persistent severe abdominal pain).

Checkpoint 2: At week 12 to 16 (mid-titration)

• Label guidance: none specific; this is a judgment checkpoint.
• Ask: is weight trending down at all, even slowly. A completely flat trend this early is unusual and worth discussing rather than assuming it is a true plateau.
• Escalation condition requiring same-week contact with the prescriber rather than waiting for the next visit: signs of gallbladder disease (right upper quadrant pain, especially after fatty meals), signs of pancreatitis, or dehydration from persistent GI symptoms.

Checkpoint 3: At the maintenance dose (week 17+ for semaglutide, week 21+ for tirzepatide, or earlier if the patient and prescriber agree to hold at a lower maintenance dose)

• Label guidance: 2.4 mg is the only labeled maintenance dose for Wegovy; 5 mg, 10 mg, and 15 mg are all labeled maintenance options for Zepbound.
• Ask: is the current dose achieving an acceptable weight-loss trajectory with tolerable side effects. If yes, there is no label requirement to push to the maximum dose.
• Site judgment: a true 12-week plateau at the maximum tolerated dose warrants a review of adherence, diet, sleep, and activity before assuming the drug has "stopped working."

Checkpoint 4: Any point, urgent evaluation warranted

• Severe, persistent abdominal pain radiating to the back (possible pancreatitis)
• Signs of gallbladder disease or biliary obstruction
• Signs of severe dehydration (dizziness, reduced urination, confusion) from vomiting or diarrhea
• Symptoms of a possible allergic reaction (facial swelling, difficulty breathing, widespread rash)

None of these checkpoints replace an individualized visit with the prescribing clinician. They are a structure for what to raise, not a protocol for self-management.

Microdosing: what the evidence does and doesn't support

"Microdosing" generally refers to using doses below the lowest labeled therapeutic dose, most often through compounded products dosed at a fraction of the approved starting dose. There is no published randomized controlled trial supporting microdosing as an effective weight-loss strategy. The lowest dose used in the pivotal semaglutide trials (0.25 mg) was included as a four-week tolerability step, not evaluated as a stand-alone therapeutic dose, and it was not associated with meaningful weight loss on its own.

Microdosing may have a narrow, individualized role for patients with severe gastrointestinal comorbidities who cannot tolerate even the standard starting dose, done under direct physician supervision with an even slower ramp. Outside that situation, dosing below label thresholds trades a small, unproven tolerability benefit for delayed or absent therapeutic effect, and patients using compounded products dosed this way should understand that efficacy at sub-label doses has not been established in trials.

Maintenance dosing decisions

The maintenance dose is whichever labeled dose achieves an acceptable weight-loss trajectory with side effects the patient can live with. It is not automatically the maximum approved dose. A patient doing well on Zepbound 10 mg has no clinical obligation to advance to 15 mg; a patient doing well on semaglutide 1.7 mg who cannot tolerate 2.4 mg after a second attempt at that step should discuss staying at 1.7 mg, or another individualized plan, with their prescriber.

Cardiovascular outcome data for semaglutide 2.4 mg in adults with overweight or obesity and established cardiovascular disease (without diabetes) has been reported from a large outcomes trial (SELECT), and this benefit was studied specifically at the 2.4 mg maintenance dose, not at lower doses. That is a relevant consideration for patients whose reason for treatment includes cardiovascular risk reduction rather than weight loss alone, but the exact magnitude of benefit should be confirmed against the original trial publication rather than repeated from memory or secondary sources.

Voluntary dose reduction after reaching a goal weight is not well studied. Available long-term data lean toward continued treatment at the effective dose being associated with sustained results, and discontinuation (partial or complete) being associated with regain. Whether a modest step-down while remaining on treatment behaves differently from full discontinuation has not been clearly established and is a reasonable question to bring to a prescriber rather than to decide independently.

Injection technique and site rotation

Injection is subcutaneous, into the abdomen (away from the navel), thigh, or upper arm, with sites rotated week to week. Repeated use of the same site can cause lipohypertrophy, a firming of the fat tissue that can reduce and make absorption less predictable; this effect is well documented for insulin and is a reasonable mechanistic concern for GLP-1 injections, though it has not been separately quantified for GLP-1 drugs in the same way it has for insulin. Very lean patients may be advised to use a shallower injection angle to avoid inadvertent intramuscular injection, which can speed absorption unpredictably and may worsen nausea. Allowing a refrigerated pen to reach room temperature before injecting, per label storage instructions, may reduce injection-site discomfort.

Managing side effects during titration

Nausea is the most common side effect and is typically tied to each new dose step, usually easing within one to two weeks once the body adapts. Reasonable, non-pharmacologic strategies include eating smaller meals, avoiding high-fat and fried foods in the first week or two after a dose increase, and staying hydrated to avoid the constipation that often follows reduced fluid intake.

Vomiting that persists beyond about two weeks at a given step, occurs more than twice in a week, or causes dehydration is a reason to hold the current dose and contact the prescriber before advancing further, not to push through. Severe, persistent abdominal pain radiating to the back is not a routine titration side effect; it warrants prompt medical evaluation for possible pancreatitis, and the medication should generally be held pending that evaluation.

Compounded GLP-1 products

Compounded semaglutide is typically dosed using the same milligram steps as Wegovy, since the underlying molecule and dose-response relationship are the same. Compounded products are not FDA-approved, however, and are not held to the same manufacturing, stability, and bioequivalence standards as the approved drug product. The FDA has stated that compounded semaglutide made from semaglutide base or salt forms may not be equivalent to the approved product; patients using compounded products should confirm current FDA guidance directly, since compounding oversight and shortage status change over time.

A frequent and avoidable error with compounded, vial-based products is confusing milligrams with milliliters. A prescribed 0.25 mg dose from a 2.5 mg/mL vial is a 0.1 mL injection, not 0.25 mL. Anyone using a vial and syringe rather than a pre-filled pen should have an explicit, written dose-to-volume conversion confirmed with the pharmacist at every dose change, and should not calculate this alone from memory.

What is established, what is plausible, and what is not established

Established: The titration schedules described above reflect current FDA-approved labeling for Wegovy and Zepbound and were the schedules used in the trials supporting each drug's approval. The five-day missed-dose window is part of both labels. Slower titration reduces early gastrointestinal side effects. Discontinuing GLP-1 treatment after a period of weight loss is associated with meaningful weight regain in trial follow-up data.

Plausible but not rigorously established: That injection site lipohypertrophy meaningfully reduces GLP-1 absorption (documented for insulin, inferred rather than separately proven for GLP-1 drugs). That a fixed rule such as "drop one dose step for every two weeks missed beyond four weeks" is optimal; this is common clinical practice rather than a studied protocol. That microdosing below labeled doses is safe long-term for patients who do not have severe GI comorbidities; it is simply unstudied for efficacy.

Not established: A head-to-head randomized comparison of semaglutide and tirzepatide titration outcomes. An optimal restart protocol after a treatment gap of more than a few weeks. Whether partial dose reduction after reaching a goal weight behaves differently from full discontinuation.

References for verification

• FDA Drugs@FDA database (for current Wegovy, Ozempic, Zepbound, and Mounjaro prescribing information): https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
• ClinicalTrials.gov (for STEP and SURMOUNT program trial registrations and results): https://clinicaltrials.gov/

Specific numeric results attributed in this article to the STEP program, the SURMOUNT program, or the SELECT cardiovascular outcomes trial should be confirmed against the original peer-reviewed publications before being used in clinical or patient-facing materials; this draft intentionally avoids citing specific journal links that could not be independently verified against the correct paper.